Table 6.
Characteristics of survivors and non-survivors in the ICU.
| Survivors (N = 29) | Non-Survivors (N = 55) | p | |
|---|---|---|---|
| Sex (Male) | 18 (62) | 38 (69) | 0.627 |
| Age (years) | 70 (61, 74) | 70 (62, 77) | 0.296 |
| APACHE II score | 12 (11, 15) | 17 (12, 22) | 0.001 |
| SOFA score | 7 (6, 8) | 8 (7, 9) | 0.009 |
| BSI | 13 (45) | 35 (64) | 0.111 |
| Diabetes Mellitus | 6 (20) | 22 (40) | 0.091 |
| Chronic Lung disease | 6 (20) | 16 (29) | 0.447 |
| Chronic Heart Failure | 0 (0) | 8 (15) | 0.046 |
| Chronic renal disease | 1 (3) | 4 (7) | 0.665 |
| Neurological disease | 3 (10) | 9 (16) | 0.531 |
| Arterial Hypertension | 16 (55) | 36 (65) | 0.479 |
| Malignancy | 3 (10) | 2 (4) | 0.335 |
| Autoimmune disease | 1 (3) | 3 (5) | - |
| Dyslipidemia | 10 (34) | 16 (29) | 0.628 |
| Coronary Artery Disease | 4 (14) | 14 (25) | 0.271 |
| Total ICU length of stay (days) | 14 (8, 25) | 13 (7, 18) | 0.349 |
| Total MV duration (days) | 11 (6, 19) | 7 (4, 12) | 0.349 |
| Total duration of sedation (days) | 9 (5, 15) | 7 (4, 12) | 0.193 |
| Appropriate Therapy | 9/13 (69) | 12/35 (34) | 0.049 |
| Steroids | 24 (83) | 49 (89) | 0.501 |
| Tocilizumab | 7 (24) | 17 (31) | 0.615 |
| Anakinra | 2 (7) | 17 (31) | 0.014 |
| Remdesivir | 9 (31) | 13 (24) | 0.602 |
| PaO2/FiO2 ratio | 164 (137, 204) | 125 (99, 156) | 0.078 |
| Crs | 40 (30, 47) | 34 (27, 42) | 0.032 |
| D-dimers | 659 (473, 1023) | 1180 (1140, 4578) | 0.027 |
| Lymphocyte Count | 500 (390, 845) | 600 (435, 738) | 0.556 |
| Ferritin | 941 (554, 1997) | 1617 (1058, 2795) | 0.204 |
Data is presented as median (25%, 75% quartiles) or n (%); BSI, Blood Stream Infection; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; MV, mechanical ventilation; Crs, compliance of the respiratory system; p, comparison between the two groups. Results by univariate analysis, chi square test, or Fisher’s exact test for categorical variables and by Mann–Whitney U test for continuous variables.